新德大藥局
  • LINE藥物諮詢
  • FB藥物諮詢
  • 最新醫藥資訊(民眾區)
  • 最新醫藥資訊(專業人員區)
  • 追蹤Instagram
  • 聯絡我們

最新醫藥資訊(民眾區)

新髮靈與柔沛的臨床試驗比較

10/30/2018

0 評論

 
收錄917名雄性禿病人之跨國多中心試驗中,排除血中睪固酮濃度<250 ng/dL者,dutasteride(新髮靈)劑量為0.02、0.1或0.5mg,治療6個月後,dutasteride(新髮靈) 0.1 mg增加髮量和頭髮粗度之效果與Finasteride(柔沛) 1 mg相當,Dutasteride(新髮靈) 0.5mg增加髮量之效果較Finasteride(柔沛)高出30%。
圖片
圖片
Dutasteride(新髮靈)用於不同嚴重程度的受試者,皆有一定程度之療效。
以Finasteride (柔沛)1 mg治療6個月後未達到顯著臨床效果的雄性禿病 人, 改以Dutasteride(新髮靈) 0.5 mg治療後,有77.4%達到程度不等之改善,於頭髮密度與粗度,平均改善了10.3%及19.8%。年輕的雄性禿病人經過24週治療後,使用dutasteride(新髮靈) 0.5 mg者單位面積髮量平均增加13根,使用Finasteride(柔沛) 1 mg者反而減少4根。

日本的研究以Dutasteride(新髮靈) 0.5 mg治療雄性禿病人,超過9成完成持續52週的治療,且頭頂和前額區域皆明顯改善,僅<1%受試者髮量減少。

參考文獻
1. Lee WS, Lee HJ, Choi GS, et al.: Guidel ines for management of androgenetic alopecia based on BASP
classification–the Asian consensus committee guideline. JEur Acad Dermatol Venereol 2013; 27:1026-1034.
2. Eun HC, Kwon OS, Yeon JH, et al.: Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63:252-258.
3. Tsunemi Y, Irisawa R, Yoshiie H, et al.: Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol 2016; 43:1051- 1058.
4. Marks LS: 5α-reductase: History and clinical importance. Rev Urol 2004; 6(suppl 9):S11-S21.
5. Blumeyer A, Tosti A, Messenger A, et al.: Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; Suppl 6:S1-S57.
6. Gupta M, Mysore V: Classifications of patterned hair loss: a review. J Cutan Aesthet Surg 2016; 9: 3-12.
7. Olsen EA, Dunlap FE, Funicella T, et al.: A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47:377-85.
8. Lucky AW, Piacquadio DJ, Ditre CM, et al.: A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50:541-53.
9. Hillmann K, Garcia Bartels N, Kottner J, et al.: A singlecentre, randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy and safety of minoxidil topical foam in frontotemporal and vertex androgenetic alopecia in men. Skin Pharmacol Physiol 2015; 28:236- 244.
10. 蔡長祐、蔡仁雨:台灣男性雄性禿之診療現況,台灣醫界,2008;51:326-330。
11. Messenger AG, Rundegren J: Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186-194. 
12. Lulic Z, Inui S, Sim WY, et al.: Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America. J Dermatol 2017 Mar 31. doi: 10.1111/1346-8138.13832. [Epub ahead of print]
13. Roberts JL, Fiedler V, Imperato-McGinley J, et al.: Clinical dose ranging studies with finasteride, a type 2 5alphareductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41:555-563.
14. Olsen EA, Whiting DA, Savin R, et al.: Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol 2012; 67:379-386.
15. Kaufman KD, Rotonda J, Shah AK, et al.: Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008; 18:400-406.
16. Rossi A, Cantisani C, Scarnò M, et al.: Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther 2011; 24:455-461.
17. Olsen EA, Hordinsky M, Whiting D, et al.: The importance of dual 5a-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebocontrolled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55:1014-1023.
18. Harcha WG, Martinez JB, Tsai TF, et al.: A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014; 70:489-498.
19. Jung JY, Yeon JH, Choi JW, et al.: Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol 2014; 53:1351-1357.
20. Shanshanwal SJ, Dhurat RS: Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol 2017; 83:47-54.
0 評論



發表回覆。

    依主管機關相關規定,專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後,即可閱讀專業人員區)。
    恕不對外開放非專業人士使用。

    每月文章

    四月 2025
    三月 2025
    九月 2024
    四月 2024
    五月 2023
    一月 2023
    十一月 2022
    十月 2022
    八月 2022
    六月 2022
    四月 2022
    三月 2022
    二月 2022
    六月 2021
    四月 2021
    三月 2021
    二月 2021
    十月 2020
    四月 2020
    三月 2020
    二月 2020
    一月 2020
    十月 2019
    九月 2019
    八月 2019
    七月 2019
    六月 2019
    五月 2019
    四月 2019
    三月 2019
    二月 2019
    一月 2019
    十二月 2018
    十一月 2018
    十月 2018
    九月 2018
    八月 2018
    七月 2018
    六月 2018
    五月 2018
    四月 2018
    三月 2018
    二月 2018
    一月 2018
    十二月 2017
    十一月 2017
    十月 2017

    類別

    全部

    RSS 訂閱

營業時間:週一至週日(全年無休)  早上九點至晚上十一點四十分  (09:00~23:40)
地址:台北市松山區饒河街204號

聯絡我們

02-2767-3402
圖片
  • LINE藥物諮詢
  • FB藥物諮詢
  • 最新醫藥資訊(民眾區)
  • 最新醫藥資訊(專業人員區)
  • 追蹤Instagram
  • 聯絡我們